{"brief_title": "A Rollover Study to Provide Chronic T-1249 to Patients Who Completed Study T1249-102", "brief_summary": "Patients who complete study T1249-102 (must be currently failing a T-20 containing regimen to participate in this study) will receive T-1249 at a dose of 200mg daily in combination with a background antiretroviral regimen for 96 weeks. Only patients that participated in study T1249-102 can participate in study T1249-105.", "condition": "HIV Infections", "intervention_type": "Drug", "intervention_name": "T-1249", "criteria": "Inclusion Criteria: - Completion T1249-102; - Currently failing a T-20 containing regimen Exclusion Criteria: - Non-completion of T1249-102.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00048217.xml"}